Potential role of sorafenib in the treatment of acute myeloid leukemia

Shahram Mori, Jorge Cortes, Hagop Kantarjian, Weiguo Zhang, Michael Andreef, Farhad Ravandi

Research output: Contribution to journalReview article

Abstract

The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.

Original languageEnglish (US)
Pages (from-to)2246-2255
Number of pages10
JournalLeukemia and Lymphoma
Volume49
Issue number12
DOIs
StatePublished - Dec 16 2008
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Renal Cell Carcinoma
Cytotoxins
Hematologic Neoplasms
Liver Neoplasms
Phosphotransferases
Pharmaceutical Preparations
sorafenib
Neoplasms

Keywords

  • AML
  • FLT3 mutations
  • MAP kinase signalling
  • Sorafenib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Potential role of sorafenib in the treatment of acute myeloid leukemia. / Mori, Shahram; Cortes, Jorge; Kantarjian, Hagop; Zhang, Weiguo; Andreef, Michael; Ravandi, Farhad.

In: Leukemia and Lymphoma, Vol. 49, No. 12, 16.12.2008, p. 2246-2255.

Research output: Contribution to journalReview article

Mori, S, Cortes, J, Kantarjian, H, Zhang, W, Andreef, M & Ravandi, F 2008, 'Potential role of sorafenib in the treatment of acute myeloid leukemia', Leukemia and Lymphoma, vol. 49, no. 12, pp. 2246-2255. https://doi.org/10.1080/10428190802510349
Mori, Shahram ; Cortes, Jorge ; Kantarjian, Hagop ; Zhang, Weiguo ; Andreef, Michael ; Ravandi, Farhad. / Potential role of sorafenib in the treatment of acute myeloid leukemia. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 12. pp. 2246-2255.
@article{46b9371b6d5048b9be4943627dfd2609,
title = "Potential role of sorafenib in the treatment of acute myeloid leukemia",
abstract = "The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.",
keywords = "AML, FLT3 mutations, MAP kinase signalling, Sorafenib",
author = "Shahram Mori and Jorge Cortes and Hagop Kantarjian and Weiguo Zhang and Michael Andreef and Farhad Ravandi",
year = "2008",
month = "12",
day = "16",
doi = "10.1080/10428190802510349",
language = "English (US)",
volume = "49",
pages = "2246--2255",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Potential role of sorafenib in the treatment of acute myeloid leukemia

AU - Mori, Shahram

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Zhang, Weiguo

AU - Andreef, Michael

AU - Ravandi, Farhad

PY - 2008/12/16

Y1 - 2008/12/16

N2 - The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.

AB - The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.

KW - AML

KW - FLT3 mutations

KW - MAP kinase signalling

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=57449110921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449110921&partnerID=8YFLogxK

U2 - 10.1080/10428190802510349

DO - 10.1080/10428190802510349

M3 - Review article

C2 - 19052971

AN - SCOPUS:57449110921

VL - 49

SP - 2246

EP - 2255

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -